ClinicalTrials.gg
RecruitingNCT06607887Updated Sep 23, 2024

The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy

A Phase 4 interventional study of IV antibiotic and Oral antibiotic in Infection Wound and Antibiotic Resistant Infection, sponsored by Minia University Hospital. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Minia University Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Wound Infection with a site in Egypt — 1 open to participants now, 1 under way, none of them phase 3. Wound Infection · Egypt.

Planned enrollment
5th of 10
300 · median 275
Started
2024
the only one that year
Phase 4
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Minia University Hospital

Among the 10 studies in Wound Infection with a site in Egypt, this one is the 5th largest by planned enrollment, is the only one that started in 2024, is one of 2 in phase 4, and was the 10th registered.

Wound Infection

270 studies on the registry are indexed under Wound Infection; 32 are open to participants now.

Browse Wound Infection studies →

Open to participants now

1 of the 10 studies in Wound Infection with a site in Egypt is open now.

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 22 Wound Infection studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Wound Infection with a site in Egypt, or all of them as a file.
02

Study summary

Comparison between postoperative parenteral prophylactic antibiotics, and oral antibiotics regarding the incidence of post laparoscopic cholecystectomy infection.

03

Conditions studied

  • Infection Wound
  • Antibiotic Resistant Infection

Browse trials for

Keywords

  • antibiotic
  • prophylaxis
  • cholecystectomy
  • postoperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged above 18 years) undergoing laparoscopic cholecystectomy.

Exclusion criteria

Exclusion Criteria:

  • patients with comorbidities (Diabetes, , ). Lost of follow-up. Patients received antibiotics within 72 hr before admission. Complicated cases involved, gangrenous and perforated cholecystitis and abscess.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    IV antibiotic

    Drug: IV antibiotic

  • Active comparator
    Oral Antibiotic

    Drug: Oral antibiotic

Interventions

  • DrugIV antibiotic

    Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.

  • DrugOral antibiotic

    Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.

06

What researchers measure

Primary outcomes

  1. Surgical site infection

    DSSI = deep surgical site infection; SSSI = superficial surgical site infection.

    Time frame: 4 weeks

Secondary outcomes

  1. Fever

    Time frame: 4 weeks

  2. Length of the hospital stay

    Time frame: 4 weeks

  3. Hematoma and Seroma formation

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2024, 3 months after the start.

Of 13 phase 4 interventional studies under Wound Infection, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2024
First posted
Sep 23, 2024
StartActual
Aug 30, 2024
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06607887
Lead sponsor
Minia University Hospital
Responsible party
Asmaa A. Elsayed (Lecturer of clinical pharmacy, Sohag University) — Principal investigator
First posted
Sep 23, 2024
Start date
Aug 30, 2024
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Sep 23, 2024

Study contacts

Asmaa A Elsayed
Contact
asmaa.abdelfattah@pharm.sohag.edu.eg
01095727201
Asmaa A Elsayed, Ph.D.
principal investigator · Sohag University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion